Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020.

Langawi MA, Byrnes C, Davies JC, Hamouda S, Kabra M, Rached SZ, Sands D, Shteinberg M, Taylor-Cousar J, Tullis E, Wainwright C.

J Cyst Fibros. 2020 Mar 7. pii: S1569-1993(20)30070-9. doi: 10.1016/j.jcf.2020.02.021. [Epub ahead of print] Review.

PMID:
32156627
2.

Lung transplantation for cystic fibrosis.

Yeung JC, Machuca TN, Chaparro C, Cypel M, Stephenson AL, Solomon M, Saito T, Binnie M, Chow CW, Grasemann H, Pierre AF, Yasufuku K, de Perrot M, Donahoe LL, Tikkanen J, Martinu T, Waddell TK, Tullis E, Singer LG, Keshavjee S.

J Heart Lung Transplant. 2020 Feb 20. pii: S1053-2498(20)31404-2. doi: 10.1016/j.healun.2020.02.010. [Epub ahead of print]

PMID:
32147452
3.

Complete versus Limited Endoscopic Sinus Surgery for Chronic Rhinosinusitis in Adults with Cystic Fibrosis.

Lee DJ, Yao CMKL, Sykes J, Rizvi L, Tullis E, Lee JM.

Otolaryngol Head Neck Surg. 2020 Feb 25:194599820904956. doi: 10.1177/0194599820904956. [Epub ahead of print]

PMID:
32093566
4.

Burkholderia cenocepacia ET12 transmission in adults with cystic fibrosis.

Blanchard AC, Tang L, Tadros M, Muller M, Spilker T, Waters VJ, LiPuma JJ, Tullis E.

Thorax. 2020 Jan;75(1):88-90. doi: 10.1136/thoraxjnl-2019-214098. Epub 2019 Nov 15.

PMID:
31732688
5.

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group.

N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.

PMID:
31697873
6.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group.

Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.

PMID:
31679946
7.

Long-term effect of CFTR modulator therapy on airway nitric oxide.

Grasemann H, Klingel M, Avolio J, Prentice C, Gonska T, Tullis E, Ratjen F.

Eur Respir J. 2020 Jan 9;55(1). pii: 1901113. doi: 10.1183/13993003.01113-2019. Print 2020 Jan. No abstract available.

PMID:
31601715
8.

The future of cystic fibrosis care: a global perspective.

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F.

Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Review. Erratum in: Lancet Respir Med. 2019 Dec;7(12):e40.

PMID:
31570318
9.

Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis.

Koutsokera A, Corriveau S, Sykes J, Coriati A, Cortes D, Vadas P, Chaparro C, McIntyre K, Tullis E, Stephenson AL.

J Cyst Fibros. 2020 Jan;19(1):119-124. doi: 10.1016/j.jcf.2019.07.011. Epub 2019 Aug 9.

PMID:
31405730
10.

Introduction to the Handbook of Life Course Health Development.

Halfon N, Forrest CB, Lerner RM, Faustman EM, Tullis E, Son J.

In: Halfon N, Forrest CB, Lerner RM, Faustman EM, editors. Handbook of Life Course Health Development [Internet]. Cham (CH): Springer; 2018.
2017 Nov 21.

11.

Life Course Research Agenda (LCRA), Version 1.0.

Halfon N, Forrest CB, Lerner RM, Faustman EM, Tullis E, Son J.

In: Halfon N, Forrest CB, Lerner RM, Faustman EM, editors. Handbook of Life Course Health Development [Internet]. Cham (CH): Springer; 2018.
2017 Nov 21.

12.

First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis.

Couroux P, Farias P, Rizvi L, Griffin K, Hudson C, Crowder T, Tarran R, Tullis E.

Pulm Pharmacol Ther. 2019 Oct;58:101819. doi: 10.1016/j.pupt.2019.101819. Epub 2019 Jul 11.

PMID:
31302339
13.

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.

Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM.

ERJ Open Res. 2019 Jun 17;5(2). pii: 00082-2019. doi: 10.1183/23120541.00082-2019. eCollection 2019 Apr.

14.

Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.

Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V.

Ann Am Thorac Soc. 2019 Jul;16(7):861-867. doi: 10.1513/AnnalsATS.201811-774OC.

PMID:
30874447
15.

Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: A systematic review and meta-analysis.

Koutsokera A, Varughese RA, Sykes J, Orchanian-Cheff A, Shah PS, Chaparro C, Tullis E, Singer LG, Stephenson AL.

J Cyst Fibros. 2019 May;18(3):407-415. doi: 10.1016/j.jcf.2018.10.013. Epub 2018 Oct 25.

PMID:
30482682
16.

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.

17.

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

18.

Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His.

Keenan K, Dupuis A, Griffin K, Castellani C, Tullis E, Gonska T.

J Cyst Fibros. 2019 Mar;18(2):265-270. doi: 10.1016/j.jcf.2018.09.002. Epub 2018 Sep 29.

PMID:
30279124
19.

High-flow nasal oxygen versus noninvasive ventilation in adult patients with cystic fibrosis: a randomized crossover physiological study.

Sklar MC, Dres M, Rittayamai N, West B, Grieco DL, Telias I, Junhasavasdikul D, Rauseo M, Pham T, Madotto F, Campbell C, Tullis E, Brochard L.

Ann Intensive Care. 2018 Sep 5;8(1):85. doi: 10.1186/s13613-018-0432-4.

20.

Cystic Fibrosis-Related Diabetes Screening in Adults: A Gap Analysis and Evaluation of Accuracy of Glycated Hemoglobin Levels.

Gilmour JA, Sykes J, Etchells E, Tullis E.

Can J Diabetes. 2019 Feb;43(1):13-18. doi: 10.1016/j.jcjd.2018.04.008. Epub 2018 May 2.

PMID:
30173928
21.

Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population.

Middleton MA, Layeghifard M, Klingel M, Stanojevic S, Yau YCW, Zlosnik JEA, Coriati A, Ratjen FA, Tullis ED, Stephenson A, Wilcox P, Freitag A, Chilvers M, McKinney M, Lavoie A, Wang PW, Guttman DS, Waters VJ.

Ann Am Thorac Soc. 2018 Jul;15(7):827-836. doi: 10.1513/AnnalsATS.201801-007OC.

PMID:
29911888
22.

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC.

N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3.

23.

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.

Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT; VX11-661-101 Study Group.

Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC.

24.

Functional integrity in children with anoxic brain injury from drowning.

Ishaque M, Manning JH, Woolsey MD, Franklin CG, Tullis EW, Beckmann CF, Fox PT.

Hum Brain Mapp. 2017 Oct;38(10):4813-4831. doi: 10.1002/hbm.23745. Epub 2017 Jul 31.

25.

Physical Activity Levels in Individuals with Cystic Fibrosis-Related Diabetes.

Currie S, Greenwood K, Weber L, Khakee H, Legasto M, Tullis E, Wu K, Tsang A, Szego E, Mathur S.

Physiother Can. 2017;69(2):171-177. doi: 10.3138/ptc.2015-92EP.

26.

Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.

Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, Sicilian L, Konstan M, Tullis E, Roach RN, Griffin K, Joseloff E, Borowitz D.

Clin Transl Gastroenterol. 2017 Mar 16;8(3):e81. doi: 10.1038/ctg.2017.10.

27.

Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.

Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E.

J Cyst Fibros. 2017 Jul;16(4):492-495. doi: 10.1016/j.jcf.2017.02.008. Epub 2017 Mar 3.

28.

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

Strug LJ, Gonska T, He G, Keenan K, Ip W, Boëlle PY, Lin F, Panjwani N, Gong J, Li W, Soave D, Xiao B, Tullis E, Rabin H, Parkins MD, Price A, Zuberbuhler PC, Corvol H, Ratjen F, Sun L, Bear CE, Rommens JM.

Hum Mol Genet. 2016 Oct 15;25(20):4590-4600. doi: 10.1093/hmg/ddw290.

29.

Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.

Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F.

Thorax. 2017 Apr;72(4):327-332. doi: 10.1136/thoraxjnl-2016-208450. Epub 2016 Aug 18.

PMID:
27539619
30.

Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients.

Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V.

J Cyst Fibros. 2017 Jan;16(1):58-63. doi: 10.1016/j.jcf.2016.06.007. Epub 2016 Jun 23.

31.

Lenticulostriate arterial distribution pathology may underlie pediatric anoxic brain injury in drowning.

Ishaque M, Manning JH, Woolsey MD, Franklin CG, Tullis EW, Fox PT.

Neuroimage Clin. 2016 Jan 23;11:167-172. doi: 10.1016/j.nicl.2016.01.019. eCollection 2016.

32.

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Kennedy S, Beaudoin T, Yau YC, Caraher E, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):348-55. doi: 10.1128/AAC.02068-15. Print 2016 Jan.

33.

Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.

Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F.

J Cyst Fibros. 2015 Nov;14(6):770-6. doi: 10.1016/j.jcf.2015.07.010. Epub 2015 Aug 9.

34.

Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.

Grasemann H, Gonska T, Avolio J, Klingel M, Tullis E, Ratjen F.

J Cyst Fibros. 2015 Nov;14(6):727-32. doi: 10.1016/j.jcf.2015.07.001. Epub 2015 Jul 11.

35.

Gaps in the inpatient management of chronic obstructive pulmonary disease exacerbation and impact of an evidence-based order set.

Kitchlu A, Abdelshaheed T, Tullis E, Gupta S.

Can Respir J. 2015 May-Jun;22(3):157-62. Epub 2015 Apr 17.

36.

Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.

Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, Tullis E, Wilcox P, Freitag A, Chilvers M, Ratjen FA.

J Cyst Fibros. 2015 Nov;14(6):755-62. doi: 10.1016/j.jcf.2015.01.007. Epub 2015 Feb 14.

37.

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V.

J Cyst Fibros. 2015 Mar;14(2):262-6. doi: 10.1016/j.jcf.2014.09.013. Epub 2014 Oct 30.

38.

In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.

Antimicrob Agents Chemother. 2015 Jan;59(1):711-3. doi: 10.1128/AAC.04123-14. Epub 2014 Oct 27.

39.

Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?

Keenan K, Avolio J, Rueckes-Nilges C, Tullis E, Gonska T, Naehrlich L.

J Cyst Fibros. 2015 May;14(3):310-6. doi: 10.1016/j.jcf.2014.09.006. Epub 2014 Oct 7.

40.

Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women.

Schram CA, Stephenson AL, Hannam TG, Tullis E.

J Cyst Fibros. 2015 May;14(3):398-402. doi: 10.1016/j.jcf.2014.09.008. Epub 2014 Oct 1.

41.

Infection prevention and control guideline for cystic fibrosis: 2013 update.

Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, Downer VS, Fliege J, Hazle LA, Jain M, Marshall BC, O'Malley C, Pattee SR, Potter-Bynoe G, Reid S, Robinson KA, Sabadosa KA, Schmidt HJ, Tullis E, Webber J, Weber DJ; Cystic Fibrous Foundation; Society for Healthcare Epidemiology of America.

Infect Control Hosp Epidemiol. 2014 Aug;35 Suppl 1:S1-S67. doi: 10.1086/676882. Epub 2014 Jul 1. No abstract available.

PMID:
25025126
42.

Electronic care records - can they fulfil their promise?

Wainwright CE, Tullis E.

J Cyst Fibros. 2014 Dec;13(6):608-9. doi: 10.1016/j.jcf.2014.04.009. Epub 2014 May 23. No abstract available.

43.

Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?

Ooi CY, Dupuis A, Gonska T, Ellis L, Ni A, Jarvi K, Martin S, Ray P, Steele L, Kortan P, Dorfman R, Solomon M, Zielenski J, Corey M, Tullis E, Durie P.

Ann Am Thorac Soc. 2014 May;11(4):562-70. doi: 10.1513/AnnalsATS.201311-412OC.

PMID:
24697796
44.

Development and evaluation of an educational website for adults with cystic fibrosis.

Anand A, Tullis E, Stephenson A, Abhyankar P.

J Cyst Fibros. 2014 May;13(3):306-10. doi: 10.1016/j.jcf.2013.10.013. Epub 2013 Dec 4.

45.

Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.

Luong ML, Chaparro C, Stephenson A, Rotstein C, Singer LG, Waters V, Azad S, Keshavjee S, Tullis E, Husain S.

Transplantation. 2014 Feb 15;97(3):351-7. doi: 10.1097/01.TP.0000437434.42851.d4.

PMID:
24305637
46.

Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis.

Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, Tullis E, Lands LC, Coates AL, Corey M, Ratjen F.

Eur Respir J. 2014 Mar;43(3):817-23. doi: 10.1183/09031936.00055513. Epub 2013 Oct 31.

47.

Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?

Ooi CY, Dupuis A, Ellis L, Jarvi K, Martin S, Ray PN, Steele L, Kortan P, Gonska T, Dorfman R, Solomon M, Zielenski J, Corey M, Tullis E, Durie P.

Thorax. 2014 Mar;69(3):254-60. doi: 10.1136/thoraxjnl-2013-203832. Epub 2013 Oct 21.

PMID:
24149827
48.

Lifecourse health development: past, present and future.

Halfon N, Larson K, Lu M, Tullis E, Russ S.

Matern Child Health J. 2014 Feb;18(2):344-65. doi: 10.1007/s10995-013-1346-2.

49.

A lifecourse approach to health development: implications for the maternal and child health research agenda.

Russ SA, Larson K, Tullis E, Halfon N.

Matern Child Health J. 2014 Feb;18(2):497-510. doi: 10.1007/s10995-013-1284-z.

PMID:
23955383
50.

Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.

Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A.

Cochrane Database Syst Rev. 2013 Jul 12;(7):CD007168. doi: 10.1002/14651858.CD007168.pub3. Review.

PMID:
23852992

Supplemental Content

Loading ...
Support Center